Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref.
studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Abd-Elsalam, 2020
  NCT04353336		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive 19%
ARCHAIC -hydroxychloroquine, 2020
  NL8490		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
9/6 inconclusive 360%
CCAP-1, 2020
  NCT04345289		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
-/- inconclusive 0%
Chen, 2020
  NCT04384380		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
21/12 inconclusive -40%
Duke university HCQ, 2020
  NCT04335552		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
4/2 no results
Gonzalez_HCQ, 2020
  NCT04391127		 RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
33/37 inconclusive -60% -28%
HAHPS, 2020
  NCT04329832		 RCThydroxychloroquineazithromycinCOVID 19 hospitalizedsome concern
42/43 inconclusive 540%
HYCOVID, 2020
  NCT04325893		 RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
124/123 inconclusive -41% 11%
NO COVID-19 (Lyngbakken), 2020
  NCT04316377		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
27/26 inconclusive -4%
OAHU-COVID19, 2020
  NCT04345692		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
10/6 inconclusive 158%
ORCHID, 2020
  NCT04332991		 RCThydroxychloroquineplaceboCOVID 19 hospitalizedlow
242/237 inconclusive 6% 2%
PROTECT B, 2020
  NCT04338698		 RCThydroxychloroquineoseltamivirCOVID 19 hospitalizedNA
-/- inconclusive -44%
RECOVERY, 2020
  NCT04381936		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
1561/3155 safety concern 8% 13%
SOLIDARITY (WHO study) HCQ, 2020
  NCT04315948		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
947/906 inconclusive 17% 10%
Tang, 2020
  ChiCTR2000029868		 RCThydroxychloroquinestandard of careCOVID 19 hospitalizedhigh
75/75 safety concern 0%
TEACH, 2020
  NCT04369742		 RCThydroxychloroquineplaceboCOVID 19 hospitalizedsome concern
67/61 inconclusive 6%
Arshad (HCQ), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
1202/409 suggested -59%
Belgian Collaborative Group on COVID-19, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
4542/3533 suggested -28%
Geleris, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
811/565 inconclusive 4% 4%
Magagnoli (HC), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedserious
97/158 safety concern safety concern145%
Novales, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
123/43 suggested -84%
Paccoud, 2020 OBShydroxychloroquinestandard of careCOVID 19 hospitalizedserious
38/46 inconclusive -10%
Sbidian (HCQ alone), 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
623/3792 safety concern 23%
Singh, 2020 OBShydroxychloroquinecontrolCOVID 19 hospitalizedcritical
-/- inconclusive 17%

COVID 19 all comers meta-analysis

ChiCTR2000030054-HCQ (Chen), 2020
  ChiCTR2000030054		 RCThydroxychloroquinestandard of careCOVID 19 all comershigh
18/12 inconclusive -31%
Gautret et al., 2020 NRahydroxychloroquinecontrolCOVID 19 all comersserious
20/16 suggested

COVID-19 mild to moderate meta-analysis

Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
  NCT04322123		 RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
221/227 safety concern 42%
HC-nCoV (Shanghai), 2020
  NCT04261517		 RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
15/15 inconclusive 0%
NCT04333654, 2020
  NCT04333654		 RCThydroxychloroquinestandard of careCOVID-19 mild to moderateNA
-/- inconclusive -40%
Zhaowei Chen, 2020
  ChiCTR2000029559		 RCThydroxychloroquinecontrolCOVID-19 mild to moderatehigh
31/31 inconclusive 0%
Zhaowei Chen, 2020
  ChiCTR2000029559		 RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
31/31 suggested
Min, 2020 OBShydroxychloroquinecontrolCOVID-19 mild to moderateNA
20/20 inconclusive

COVID-19 severe or critically meta-analysis

HYDRA, 2020
  NCT04315896		 RCThydroxychloroquineplaceboCOVID-19 severe or criticallyNA
75/77 inconclusive -1%
REMAP-CAP-HCQ, 2020
  NCT02735707		 RCThydroxychloroquinestandard of careCOVID-19 severe or criticallyNA
61/81 inconclusive 4%
Mahevas, 2020 OBShydroxychloroquinestandard of careCOVID-19 severe or criticallyserious
84/97 inconclusive -35%
Yu, 2020 OBShydroxychloroquinecontrolCOVID-19 severe or criticallycritical
48/520 suggested -61%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons